Extendicare (TSE:EXE – Get Free Report) had its target price reduced by research analysts at Desjardins from C$40.00 to C$39.00 in a report released on Monday,BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. Desjardins’ target price suggests a potential upside of 21.16% from the stock’s previous close.
EXE has been the topic of a number of other research reports. BMO Capital Markets increased their price objective on shares of Extendicare from C$30.00 to C$38.00 in a report on Wednesday, May 13th. TD boosted their target price on shares of Extendicare from C$32.00 to C$39.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Canaccord Genuity Group upgraded shares of Extendicare to a “strong-buy” rating in a research report on Monday, May 11th. Finally, National Bank Financial increased their price target on shares of Extendicare from C$34.00 to C$40.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of C$35.44.
Extendicare Price Performance
Extendicare (TSE:EXE – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported C$0.32 earnings per share for the quarter. Extendicare had a net margin of 6.99% and a return on equity of 45.35%. The firm had revenue of C$611.04 million for the quarter. Equities analysts expect that Extendicare will post 0.6134729 EPS for the current fiscal year.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading
- Five stocks we like better than Extendicare
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
